GlassScriptPhysician profile
Marjan Yousefi
NPI 1770742249
$4,164.31
in general payments reported to CMS, 2019-2025
28 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,287 · 2020: $188 · 2021: $143 · 2022: $499 · 2023: $673 · 2024: $483 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.52 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.64 | 2019-2025 | Skyrizi |
| Galderma Laboratories, L.P. | $463.24 | 2019-2025 | Oracea, Aklief, Nemluvio |
| Lilly USA, LLC | $393.02 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $348.04 | 2022-2025 | Opzelura |
| Ucb, INC. | $316.29 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $295.20 | 2019-2023 | |
| Merz North America, INC. | $255.53 | 2019-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $213.89 | 2019-2023 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $205.74 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $200.22 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $116.05 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.47 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Mayne Pharma Commercial LLC | $78.76 | 2019 | |
| Sandoz INC. | $69.61 | 2019 | |
| Amgen INC. | $69.58 | 2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $62.48 | 2025 | |
| Janssen Biotech, INC. | $62.34 | 2022-2025 | Tremfya |
| Celgene Corporation | $54.25 | 2019 | |
| Leo Pharma INC. | $52.77 | 2019 | |
| Almirall LLC | $49.81 | 2019 | |
| Epi Health, LLC | $47.99 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $46.43 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $46.12 | 2023-2024 | Vtama |
| Genzyme Corporation | $33.06 | 2023 | |
| Vyne Pharmaceuticals INC. | $26.27 | 2020 | |
| Aclaris Therapeutics, INC. | $19.77 | 2019 | |
| Botanix Sb INC | $18.54 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $17.20 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjan Yousefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.